Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.60 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.60 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.60 |
| ▸ | THRB | P10828 | 7/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217975 | 0.90 | TGFBR1 (0.54) | TGFBR1TGFBR2MAP3K20THRBCYP2D6 | |
| SCHEMBL23217933 | 0.88 | TGFBR1 (0.54) | TGFBR1TGFBR2MAP3K20THRBCYP2D6 | |
| SCHEMBL24312011 | 0.87 | TGFBR1 (0.61) | TGFBR1TGFBR2MAP3K20THRBCYP2D6 | |
| SCHEMBL24311950 | 0.85 | TGFBR1 (0.62) | TGFBR1TGFBR2MAP3K20THRBCYP2D6 | |
| SCHEMBL24312358 | 0.82 | TGFBR1 (0.48) | TGFBR1TGFBR2MAP3K20THRBCYP2D6 | |
| SCHEMBL24311946 | 0.82 | TGFBR1 (0.60) | TGFBR1TGFBR2MAP3K20THRBCYP2D6 | |
| SCHEMBL24312356 | 0.80 | TGFBR1 (0.62) | TGFBR1TGFBR2MAP3K20THRBCYP2D6 | |
| SCHEMBL24312353 | 0.79 | TGFBR1 (0.64) | TGFBR1TGFBR2MAP3K20THRBCYP2D6 | |
| SCHEMBL24311953 | 0.79 | TGFBR1 (0.58) | TGFBR1TGFBR2MAP3K20THRBCYP2D6 | |
| SCHEMBL24312357 | 0.79 | TGFBR1 (0.53) | TGFBR1TGFBR2MAP3K20THRBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076905-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021072330-A1 | GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |